Caidya

Caidya is a CRO that provides clinical development services, with expertise in oncology, hematology, and rare disease. The company emphasizes agility, global reach, and patient-centric solutions. It was formed through the merger of dMed and Clinipace in 2021 and rebranded as Caidya in 2022. In 2025, it received a strategic growth investment from Rubicon Founders, and in 2026 it combined with Simbec-Orion.

Caidya was formed through the merger of dMed and Clinipace in 2021, and rebranded as Caidya in 2022. In 2024, Barbara Lopez Kunz was named CEO. In 2025, Caidya received a strategic growth investment of $165M from Rubicon Founders. In 2026, Caidya combined with Simbec-Orion.

1. Your Clinical Development Partner | Caidya
2. About Caidya, Your Future-Ready CRO | Caidya
3. Environmental, Social, and Governance | Caidya
4. Leadership Team - Caidya®